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Abstract
Purpose: To evaluate the influence of the maximum involvement of biopsy core (MIBC) on outcome for prostate
cancer patients treated with dose-escalated external beam radiotherapy (EBRT).
Methods and materials: The outcomes of 590 men with localized prostate cancer treated with EBRT (≥75 Gy) at a
single institution were retrospectively analyzed. The influence of MIBC on freedom from biochemical failure (FFBF),
freedom from metastasis (FFM), cause-specific survival (CSS), and overall survival (OS) was compared to other
surrogates for biopsy tumor volume, including the percentage of positive biopsy cores (PPC) and the total
percentage of cancer volume (PCV).
Results: MIBC correlated with PSA, T-stage, Gleason score, NCCN risk group, PPC, PCV, and treatment related
factors. On univariate analysis, MIBC was prognostic for all endpoints except OS; with greatest impact in those with
Gleason scores of 8–10. However, on multivariate analysis, MIBC was only prognostic for FFBF (hazard ratio [HR] 1.9,
p= 0.008), but not for FFM (p= 0.19), CSS (p= 0.16), and OS (p= 0.99).
Conclusions: In patients undergoing dose-escalated EBRT, MIBC had the greatest influence in those with Gleason
scores of 8–10 but provided no additional prognostic data as compared to PPC and PCV, which remain the
preferable prognostic variables in this patient population.
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Introduction
Pretreatment prognostic indices predictive of outcome
in patients with clinically localized prostate cancer typic-
ally rely on risk-factors including: prostate-specific anti-
gen (PSA), clinical T-stage, and biopsy Gleason score
(GS) [1,2]. More recent models have evaluated the prog-
nostic utility of incorporating biopsy tumor volume. Sur-
rogates for cancer volume have included the percentage
of positive cores (PPC) at the time of prostate biopsy
[3,6] and the total percentage of cancer volume (PCV)
in all of the biopsy cores [7,8]. In a recent analysis we
demonstrated that in a cohort of patients treated with
dose-escalated EBRT, PCV was superior to PPC as a
prognostic variable for prediction of clinical outcomes.
In addition, PCV was found to add prognostic signifi-
cance for all end-points, including overall survival (OS)
[8]. However, calculating PCV is time consuming; fur-
thermore, it is possible that a moderate volume of can-
cer involved in a large number of cores is less important
than a dominant lesion involving a large volume of can-
cer in one or more cores. The maximum involvement of
a single biopsy core has previously been demonstrated
to correlate with worse pathologic features and higher
biochemical failure following radical prostatectomy;
however, it has not previously been assessed in patients
treated with EBRT. Therefore, this study aimed to assess
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the prognostic significance of the maximum involvement
of biopsy core by cancer (MIBC) as compared to both
PPC and PCV in a cohort of patients treated with dose-
escalated EBRT for prostate cancer.
Patients and methods
Patients
From 1998 to 2008, 718 men with clinically localized
prostate adenocarcinoma were consecutively treated at
the University of Michigan with definitive external beam
radiotherapy to a minimum dose of 75 Gy with or with-
out neo-adjuvant and/or adjuvant androgen deprivation
therapy (ADT). Prior to treatment, patients were risk
stratified into low-, intermediate-, and high-risk groups
based on standard NCCN criteria. Staging evaluation
was performed per standard clinical practice. Symptom-
atic patients and/or those with NCCN-defined high-risk
features were routinely staged with pelvic CT and bone-
scan. Patients with evidence of metastatic disease were
excluded from the analysis.
All prostate core biopsies were reviewed by dedicated
uropathologists at the University of Michigan who
reported Gleason score, number of positive cores, and
percent cancer involvement for each core. The max-
imum involvement of biopsy core (MIBC) was defined
as the highest percentage of cancer present in one or
more individual biopsy cores from all sampled cores.
Percentage of positive cores (PPC) and the percentage
cancer volume (PCV) were both calculated as previously
described [6,8].
Treatment
All patients underwent CT-based treatment planning
and were treated with 3D-conformal RT (3D-CRT) or
intensity modulated RT (IMRT). The median prescribed
dose was 78 Gy (inter-quartile range [IQR] 76–78) using
daily fractions of 1.8 to 2.0 Gy. Treatments were planned
to ensure 95% coverage of the planning target volume
(PTV) by the prescription isodose level. Clinical target
volumes (CTV) were typically based upon the NCCN
risk-stratification criteria such that low-risk patients
were treated to the prostate only, intermediate-risk
patients to the prostate and seminal vesicles, and high-
risk patients to the pelvic lymph nodes to 45 Gy fol-
lowed by a boost to the prostate and seminal vesicles.
The frequency and duration of ADT were as follows:
low-risk (11%, median 4.1 months), intermediate-risk
(27%, median 6.6 months), and high-risk (90%, median
23.0 months).
Outcome assessments
Patients were routinely followed at 3–6 month intervals
for the first 5 years and every 6 to 12 months thereafter.
Freedom from biochemical failure (FFBF) was defined
based upon the ASTRO Phoenix definition (20). Free-
dom from metastasis (FFM) was defined as the absence
of any clinical, radiographic, or pathologic evidence of
metastatic disease. Cause specific survival (CSS) was
defined as death attributed to prostate cancer or death
in any patient with either castrate-resistant prostate can-
cer or evidence of metastatic disease prior to death. OS
was defined as death due to any cause.
Statistical methods
One-way analysis of variance (ANOVA) was used for the
comparison between MIBC groups and continuous vari-
ables while the chi-square (CS) test was used for analysis
between MIBC groups and categorical variables. Univari-
ate survival analyses were conducted using the log-rank
test and Kaplan-Meier method. Multivariate analyses
were conducted using Cox proportional hazards models.
Receiver operator characteristic (ROC) curves were used
to evaluate the relative predictive capacity of MIBC
compared to other cancer volume metrics (PPC, PCV),
used as continuous variables and correlated with clinical
end-points at 7 years. The cut-point that best discrimi-
nated patient outcome based on different metrics was
computed using the maximum likelihood ratio. All stat-
istical analysis was performed using MedCalc (v11.4.4.0,
MedCalc Software, Mariakerke, Belgium) using 2-sided
tests with a p-value <0.05 considered significant.
Results
Clinical characteristics
Data on MIBC, PPC, and PCV was available for 590 of
718 (82%) men with a median age of 69 years (IQR: 63–
74) and a median follow-up of 57 months (IQR: 34–81).
The median number of biopsy cores sampled was 8
(IQR: 6–12, range: 4–86) with a median PPC of 33.3%
(IQR: 17-60%; range: 3.7-100%), a median PCV of 10%
(IQR: 2.5-25%; range: 0.14-95%), and a median MIBC of
30.0% (IQR: 10-70%, range 1-100%).
The relationship between MIBC and other clinical and
tumor related characteristics is shown in Table 1. MIBC
was associated with NCCN risk group as well as indi-
vidual risk features including PSA, T-Stage, and Gleason
score (all p-values <0.001) with increasing MIBC quartiles
associated with more advanced clinical features. When
divided by NCCN risk-group, the proportion of patients
with low-, intermediate-, and high-risk disease within the
1st MIBC quartile was 52%, 35% and 13%, respectively,
while within the 4th MIBC quartile it was 5%, 39%, and
56%. There were also differences in the use of pelvic RT
and ADT between MIBC subgroups, such that only 12%
and 29% in 1st MIBC quartile received pelvic RT and
ADT, respectively, while 55% and 66% of patients in 4th
quartile received these treatments.
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Both PCV and PPC were significantly correlated with
MIBC (p <0.001) with a much weaker correlation be-
tween MIBC and PPC (r = 0.52, 95%CI: 0.45-0.57,
Figure 1A) as compared to MIBC and PCV (r = 0.77,
95%CI: 0.73-0.80, Figure 1B).
Association between MIBC and clinical outcome
When analyzed by quartile, MIBC demonstrated signifi-
cant correlation with FFBF (p < 0.0001), FFM (p < 0.005),
and CSS (p < 0.007) and borderline association with OS
(p= 0.06), (Table 2). For all end-points, the 4th quartile
(70%) exhibited significantly worse clinical behavior than
the lower three quartiles. When the 4th quartile was
excluded, there was only a difference in FFBF (p < 0.009)
across the first three quartiles but no difference in FFM
(p= 0.12), CSS (p= 0.29), or OS (p= 0.30) (Table 2).
Since ADT use was highly correlated with increasing
risk-features there was also a close correlation between
increasing MIBC and ADT use (No ADT: MIBC median
20 (IQR:5–50); with ADT: MIBC median 60 (10–95),
ANOVA p< 0.001). After dividing the data by ADT use
MIBC was prognostic only for BF (p = 0.02) and metasta-
sis (p = 0.03) in those treated with RT alone and was only
prognostic for BF in those treated with RT plus ADT
(p = 0.01).
To identify the optimal cut-point for MIBC stratifica-
tion, ROC curves were generated for each endpoint
using MIBC as a continuous variable. At 7-years, MIBC
was predictive for FFBF (area under the curve [AUC]:
0.67, 95% CI: 0.60-0.74, p < 0.0001), FFM (AUC: 0.67,
95% CI: 0.58-0.75, p= 0.004), and CSS (AUC: 0.79, 95%
CI: 0.69-0.87, p= 0.0002), but not OS (AUC: 0.60, 95%
CI: 0.51-0.69, p= 0.075). A number of different cut-
points could be utilized for further analysis and indeed
Table 1 Clinical and treatment characteristics for maximum involvement of biopsy core (MIBC) stratified by quartile
Variable MIBC by quartile
1st (<10%) 2nd (<30%) 3rd (<70%) 4th (≥70%) p
Patients (n) 144 135 147 164
Age (y), median (IQR) 68 (62–73) 69 (63–74) 69 (62–74) 71 (64–75) 0.48*
PSA (ng/mL), median (IQR) 7.6 (5.3-10.6) 7.2 (4.9-10.4) 7.5 (5.0-12.2) 10.4 (6.7-20.4) <0.001*
<10 70% 73% 65% 48% <0.0001†
10-20 23% 17% 25% 27%
≥20 7% 10% 10% 26%
T-stage <0.0001†
T1-T2a 91% 92% 79% 59%
T2b-T2c 6% 4% 17% 26%
T3-T4 3% 4% 4% 15%
Gleason score <0.0001†
2-6 67% 54% 22% 8%
7 26% 39% 60% 49%
8 5% 6% 10% 17%
9-10 2% 1% 8% 26%
Percent cores positive 17% (13-33%) 25% (17-40%) 41% (25-58%) 63% (46-83%) <0.001*
Percent cancer volume 0.8% (0.5-1.7%) 2.9% (1.9-5.0%) 11.7% (6.7-18.8%) 33.6% (20.8-48.9%) <0.001*
NCCN risk group <0.0001†
Low 52% 37% 14% 5%
Intermediate 35% 45% 59% 39%
High 13% 18% 27% 56%
RT dose (Gy), median (IQR) 77 (76–78) 77 (76–78) 77 (77–78) 78 (77–78) <0.001*
Pelvic RT 12% 17% 25% 55% <0.0001†
ADT use 29% 31% 35% 66% <0.0001†
ADT duration, median (IQR) 6.9 (6.0-18.7) 6.1 (4.0-18.7) 6.4 (6.0-24.4) 20.9 (6.3-25.6) 0.2*
Abbreviations: IQR = inter-quartile range; PSA = prostate-specific antigen; NCCN=National Comprehensive Cancer Network; RT = radiotherapy; ADT = androgen
deprivation therapy.
*Analysis of variance.
†Chi-square test.
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given close association between increasing risk-features
and increasing MIBC if MIBC was addressed in 10%
increments any cut-point >10% was associated with BF
while any cut-point >40% was associated with metastasis
and death from prostate cancer. From these analyses
MIBC had the strongest prognostic association with
death from prostate cancer (AUC 0.79) and a cut-point
of 60% was selected for further evaluation as this value
was most closely associated with CSS, (negative predict-
ive value [NPV] 97% and positive predictive value of
30.5%) while still maintaining modest prognostic signifi-
cance for FFBF (NPV 64%) and FFM (NPV 87%).
On univariate analysis, those with MIBC of 60% or
greater (n = 196) had worse clinical outcome than those
with MIBC of less than 60% (n = 394). Stratification
according to this MIBC cut-point of 60% was prognostic
for FFBF (p < 0.0001, HR:2.7 [95% CI: 1.7- 4.1]), FFM
(p= 0.006, HR:2.4 [95%CI: 1.2-4.5]), and CSS [p = 0.0088,
HR: 3.8 [95% CI: 1.3-11.0]) with borderline association
with OS (p=0.055, HR: 1.5 [95%CI: 0.9-2.2]) (Figure 2A-D).
Multivariate analysis
Given the correlation between MIBC and conven-
tional clinical risk-groups, multivariate Cox-proportional
hazards modeling was performed stratifying patients by
NCCN risk-grouping and the best-identified cut-point
for MIBC (60%). The presence of high-risk disease was
the strongest predictor of decreased FFBF, FFM, CSS,
and OS with hazard ratios (HR) ranging from 3.0 to 6.9
(Table 3). Conversely, after including MIBC intermediate-
risk disease was not prognostic for any of these endpoints.
However, after adjusting for NCCN risk-groups, a large
volume of cancer in any one core (as defined by MIBC
>60%) provided further prognostic significance for FFBF
(p= 0.008, HR:1.9 [95% CI: 1.2-2.9]) but did not influence
any other end-points. In an additional multivariate ana-
lysis, MIBC was analyzed as continuous variable and after
controlling for risk-group, each 10% increment in MIBC
yielded an increased risk for biochemical failure
(p= 0.0008, HR: 1.13 [95% CI: 1.1-1.2]) with no impact
upon other clinical end-points.
a b
Figure 1 (a) Correlation between maximum involvement of biopsy core (MIBC) and (a) percentage of positive cores (PPC) and (b)
percentage of cancer volume (PCV).
Table 2 Univariate Analysis of Clinical Outcome As A Function of MIBC By Quartile
Quartile N FFBF FFM CSS OS
5 yr 8 yr 5 yr 8 yr 5 yr 8 yr 5 yr 8 yr
<10% 144 91% 91% 97% 95% 100% 96% 91% 72%
(88–94) (88–94) (95–99) (92–98) (93–99) (88–94) (55–79)
<30% 134 93% 79% 97% 93% 100% 100% 96% 92%
(90–96) (72–86) (95–99) (88–98) (94–98) (89–95)
<70% 147 82% 70% 95% 83% 99% 99% 95% 82%
(88–86) (63–77) (93–97) (77–89) (98–100) (98–100) (93–97) (77–87)
70 +% 164 74% 51% 91% 82% 94% 94% 87% 77%
(71–78) (43–59) (88–94) (77–87) (92–96) (92–96) (84–90) (72–82)
p-value Overall <0.0001 0.0047 0.0071 0.061
p-value Quartiles 1-3 0.009 0.12 0.29 0.30
Rates at five and eight years along with the standard error of the mean.
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To further evaluate the influence of MIBC as compared
to PPC and PCV univariate analysis and multivariate
analysis was performed for BF using relevant pre-
treatment and treatment-related features (Table 4). When
only MIBC was included in a multivariate model (either
as a continuous variable [presented] or by 60% cut-point
[not presented]) MIBC did add prognostic value for BF
(Model #1). Each 1% increase in MIBC resulted in a 1%
increase in the relative risk of biochemical failure even
after controlling for other clinical features. However, once
either PPC (Model #2) or PCV (Model #3) were intro-
duced MIBC no longer retained prognostic significance
while both PPC and PCV did. Similar analyses were
performed for metastasis, CSS, and OS and in each
case MIBC did not add prognostic value, and so they
were not presented.
Given the close association between Gleason score
and MIBC which was 10% (IQR:5-25%), 40% (IQR:20-
70%) and 80% (IQR:50-90%) for Gleason 2–6, 7, and 8–
10, respectively (p < 0.001, ANOVA) we assessed whether
MIBC had differing prognostic significance as a function
of Gleason score. MIBC had no prognostic impact in
those with Gleason 2–6 or 7 for any clinical end-point
assessed (all p > 0.1); however, if Gleason was combined
a b
c d
Figure 2 Kaplan-Meier estimates of (a) freedom from biochemical failure, (b) freedom from metastasis, (c) cause-specific survival, and
(d) overall survival as a function of maximum involvement of biopsy core (MIBC). Cut-point of 60% generated from receiver operating
characteristic curve analysis.
Table 3 Multivariate analysis for all clinical outcomes stratified for NCCN risk group and the best-identified cut-point
for MIBC (60%)
Covariate FFBF FFM CSS OS
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
NCCN risk group
Low Reference Reference Reference Reference
Intermediate 1.7 (0.83-3.4) 0.15 2.8 (0.80-9.8) 0.11 2.1 (0.23-19.7) 0.51 1.2 (0.57-2.5) 0.65
High 3.2 (1.6-6.5) 0.001 4.6 (1.3-16.2) 0.02 6.9 (0.8-59.6) 0.08 3.0 (1.5-6.1) 0.002
MIBC
<60% Reference Reference Reference Reference
≥60% 1.9 (1.2-2.9) 0.008 1.6 (0.81-3.1) 0.19 2.2 (0.72-6.9) 0.16 1.0 (0.59-1.7) 0.99
Abbreviations: MIBC =maximum involvement of biopsy core; FFBF = freedom from biochemical failure; FFM= freedom from metastasis; CSS = cause specific survival;
OS = overall survival; HR = hazard ratio; CI = confidence interval.
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in those with scores of 2–7 the MIBC did predict worse
BF using a cut-point of 60% (p = 0.0036, HR: 2.0 (95%
CI:1.2-3.4). Nevertheless, even in this combined Gleason
2–7 group (n = 474) MIBC did not influence metastasis,
CSS, or OS (all p-values >0.1, data not shown). However,
in the 116 patients with Gleason 8–10 MIBC clearly
influenced clinical outcome (Figures 3A-3D) with worse
BF (p = 0.0098, HR:3.3 (95%CI:1.6-6.8), metastasis
(p = 0.038, HR:6.5 (95%CI:2.1-20)), CSS (p = 0.025), and
borderline for OS (p = 0.073, HR:2.2 (95%CI:1.0-4.9)).
Interestingly, in those with Gleason 8–10 and MIBC
>60% (n = 37, median follow-up 57 months) there were
no deaths from PCa while in those with Gleason 8–10
and MIBC<60% (n = 79, median follow-up 39 months)
there were 9 deaths from PCa (Figure 3C). (Since there
were no deaths in those with MIBC<60% and Gleason
scores of 8-10 a hazard ratio could not be determined).
Finally, we evaluated the hypothesis that MIBC would
have greater prognostic significance in patients with a low
total volume of cancer where the impact of a single high
volume core might be more noticeable. Within this data
set, we previously identified an optimal cut-point of 22.5%
for total biopsy cancer volume (PCV <22.5% [n= 393];
PCV ≥22.5% [n=144]), which on multivariate analysis
predicted worse outcome for all clinical endpoints, includ-
ing CSS (HR 3.9, p=0.01) [8]. Of the 144 patients with a
large total cancer volume, MIBC (stratified by 60%) was
not prognostic for any end-point (p > 0.3 for all). However,
in the 393 patients with a smaller total volume of cancer,
67 patients (17%) had maximum core involvement of
≥60% with a trend toward worse FFBF (HR: 1.7 [95%CI:
0.8-3.9], p= 0.09) and FFM (HR: 2.2 [95%CI:0.7-6.7],
p= 0.07) but no impact upon CSS or OS (p> 0.5 for each).
Discussion
One limitation to predicting outcome in men undergo-
ing radiotherapy for prostate cancer is the poor ability to
define the volume of cancer present at the time of diag-
nosis. Both PPC and PCV have previously been evalu-
ated as prognostic tools for patients treated with
radiation therapy [3-8]. In contrast, data on the prognos-
tic impact of MIBC in prostate cancer are scarce; to our
Table 4 Univariate and Multivariate Models For Freedom From Biochemical Failure
Variable Univariate Analysis Multivariate Model # 1
Maximum Core Only
Multivariate Model #2 MIBC+
Percent Positive Cores
Multivariate Model #3 MIBC+
Percent Cancer Volume
p-value Hazard Ratio
(95% CI)
p-value Hazard Ratio
(95%CI)
p-value Hazard Ratio
(95%CI)
p-value Hazard Ratio
(95%CI)
Age 0.62 0.99 (0.97-1.02) 0.23 0.99 (0.96-1.01) 0.40 0.99 (0.97-1.01) 0.48 0.99 (0.97-1.02)
PSA <0.0001 5.7 (3.6-9.5) <0.0001 4.6 (2.3-9.3) <0.0001 4.7 (2.3-9.7) 0.0001 4.5 (2.2-9.4)
T-stage
T1-T2a Reference Reference Reference Reference
T2b-T2c 0.0065 2.0 (1.2-3.3) 0.48 1.2 (0.70-2.2) 0.82 1.1 (0.59-1.9) 1.0 1.00 (0.55-1.8)
T3-4 <0.0001 3.3 (1.9-5.6) 0.67 1.2 (0.60-2.2) 0.83 1.1 (0.55-2.1) 0.91 0.96 (0.49-1.9)
Gleason Score
2-6 Reference Reference Reference Reference
7 0.0004 2.6 (1.5-4.3) 0.17 1.6 (0.82-3.1) 0.45 1.3 (0.67-2.5) 0.58 1.2 (0.61-2.4)
8-10 <0.0001 4.9 (2.8-8.9) 0.02 2.8 (1.2-6.9) 0.027 2.8 (1.1-6.7) 0.07 2.3 (0.93-5.8)
ADT Use
No Reference Reference Reference Reference
Yes 0.0001 2.2 (1.5-3.3) 0.82 0.94 (0.53-1.7) 0.68 0.88 (0.49-1.6) 0.80 0.93 (0.51-1.7)
Pelvic RT
No Reference Reference Reference Reference
Yes <0.0001 2.7 (2.0-3.8) 0.32 0.68 (0.32-1.5) 0.20 0.59 (0.27-1.3) 0.30 0.65 (0.29-1.5)
RT Dose 0.10 1.2 (0.97-1.4) 0.95 1.01 (0.78-1.3) 0.71 1.05 (0.82-1.3) 0.70 1.05 (0.81-1.4)
Cancer Volume Metrics
Maximum Biopsy Core <0.0001 1.02 (1.01-1.02) 0.12 1.01 (1.00-1.02) 0.27 1.00 (0.99-1.02) 0.33 1.00 (1.0-1.02)
Percent Positive Cores <0.0001 1.02 (1.01-1.03) 0.019 1.01 (1.00-1.02)
Percent Cancer Volume <0.0001 1.02 (1.02-1.03) 0.03 1.02 (0.98-1.04)
All analyses done by Cox Proportional Hazards regression with variables modeled as continuous variables except where indicated.
Abbreviations: MIBC =maximum involvement of biopsy core; PSA = Prostate Specific Antigen; ADT =Androgen Deprivation Therapy; RT = Radiation Therapy;
HR = hazard ratio; CI = confidence interval.
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knowledge this is the first analysis on the utility of MIBC
in patients treated with EBRT.
In one previous report MIBC was identified as an in-
dependent determinant of histological disease progres-
sion in a cohort of patients with low-risk prostate cancer
undergoing active surveillance [9]. Moreover, in a com-
prehensive analysis done by Brimo et al., the authors
tested the prognostic value of seven different morpho-
metric measurements of tumor extent from prostate
needle core biopsy tissue, including MIBC, in a group of
patients treated with radical prostatectomy. On univari-
ate analysis the time to PSA recurrence was marginally
associated with greatest percentage of cancer (p = 0.06)
which was defined in a similar manner to how we
defined MIBC [10].
In the present study, MIBC was closely correlated with
other clinical risk-features as well as PCV (r = 0.77) and
less so with PPC (r = 0.52). Given the close association
with clinical risk-features, it is not surprising that on
univariate analysis MIBC was associated with clinical
outcome for all end-points except OS. However, on
multivariate analysis either after controlling for NCCN
risk-group or for other clinical and treatment-related
features, MIBC only added prognostic value for FFBF,
but not for any of the other clinically relevant end-
points. Despite limited prognostic significance over all
patients; when MIBC was assessed independently in
patients with Gleason scores of 8–10 it did correlate
significantly with greater BF, metastasis, and death from
prostate cancer with borderline association with OS
while in those with Gleason scores of 2–7 it only
appeared to influence BF.
Conversely, within the same dataset, PCV predicted a
worse outcome for all end-points on multivariate analysis,
including FFBF (HR 1.9, p= .003), FFM (HR 1.7, p= .09),
CSS (HR 3.9, p= .01), and OS (HR 1.8, p= .02) even after
accounting for PPC.[8] Thus, at present, PPC and PCV
should remain the standard metrics for estimating pros-
tate cancer volume, given the additional prognostic data
they provide as compared to MIBC for patients undergo-
ing definitive EBRT. Interestingly, as previously observed
when any of the measures of cancer volume (MIBC, PPC,
or PCV) were included in multivariate models clinical T-
stage was no longer prognostic which is suggestive that
these measures of cancer volume are likely more clinically
relevant than T-stage assessed by digital rectal exam.[8,11]
The strengths of study include the large patient number,
restriction to patients undergoing dose-escalated EBRT,
and analysis of clinically relevant endpoints, including
FFM, CSS, and OS. Limitations arise from the study are
significant given that it represents retrospective analysis
from a single institutions without central pathologic re-
view or validation of these findings. In addition, the cor-
relation between MIBC and both the use of pelvic RT and
ADT certainly cloud the ability to independently evaluate
the impact of each of these factors while the follow-up of
a b
c d
Figure 3 Failure patterns for patient cohort based on Gleason 8–10 stratified by having less than or equal to 60% MIBC vs. greater
than 60% MIBC. (a) FFBF. (b) FFM. (c) CSS (d) OS.
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only 5 years limits conclusions about more long-term
end-points such as metastasis and CSS.
Conclusion
Although a simple and an easily obtained measure of
prostate cancer volume, MIBC provided no additional
prognostic data compared to PPC and PCV, and indeed
was less relevant then either of these other metrics.
Therefore, both PPC and PCV are preferable end-points
to be used as prognostic tools. However, if future ana-
lyses of MIBC are undertaken we would suggest a focus
upon patients with the highest Gleason scores where
MIBC had the greatest suggestion of possible value.
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